Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500

Untangling the ErbB signalling network

Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974

Real time quantitative PCR.Preprint

Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180

Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767

A novel method for real time quantitative RT-PCR.Preprint

Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090

ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617

The EGF receptor family as targets for cancer therapy

Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Gianni, L., Pieńkowski, T., Im, Y., Roman, L., Tseng, L., Liu, M.-C., Lluch, A. M., Starosławska, E., de la Haba-Rodríguez, J., Im, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,427

Tyrosine Kinases as Targets for Cancer Therapy

Krause, D. S., & Etten, R. A. V. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,402

The ErbB/HER family of protein-tyrosine kinases and cancer

Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,408

Deconstructing the molecular portraits of breast cancer

Prat, A., & Perou, C. M. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.11.003 · Cited by 1,418

The discovery of receptor tyrosine kinases: targets for cancer therapy

Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227

Targeting HER2-positive breast cancer: advances and future directions

Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00579-0 · Cited by 1,160

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,170

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,126

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P. H., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,117

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

Arteaga, C. L., & Engelman, J. A. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.025 · Cited by 1,048

Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis

Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952

Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

Nahta, R., Yu, D., Hung, M., Hortobágyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 928

An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

Burgess, A. W., Cho, H., Eigenbrot, C. W., Ferguson, K. M., Garrett, T., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 936

Treatment of HER2-positive breast cancer: current status and future perspectives

Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 878

Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941

Junttila, T. T., Akita, R. W., Parsons, K. L., Fields, C. T., Phillips, G. D. L., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 848

HER2-Low Breast Cancer: Pathological and Clinical Landscape

Tarantino, P., Hamilton, E. P., Tolaney, S. M., Cortés, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 804

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793

Deciphering breast cancer: from biology to the clinic

Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 792

Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer

Baselga, J. M., & Arteaga, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.890 · Cited by 726

Epidermal Growth Factor Receptor Targeting in Cancer

Mendelsohn, J. M., & Baselga, J. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 705

Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy

Baselga, J. M., Gelmon, K. A., Verma, S., Wardley, A. M., Conte, P., Miles, D. W., Bianchi, G., Cortés, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 646

ErbB Receptors: Directing Key Signaling Networks Throughout Life

Holbro, T., & Hynes, N. E. (2004) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 660

A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy

Lee-Hoeflich, S. T., Crocker, L., Yao, E. S., Pham, T. Q., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 645

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer

Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636

Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models

Scheuer, W., Friess, T., BURTSCHER, H. J., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 634

The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells

Nahta, R., Hung, M., & Esteva, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3856 · Cited by 614

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors

Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 615

The role of HER2 in cancer therapy and targeted drug delivery

Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 557

Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line

Nagy, P., Friedländer, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J. J., & Jovin, T. M. (2005) · Cancer Research · doi:10.1158/0008-5472.473.65.2 · Cited by 527

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Mitri, Z. I., Constantine, T., & O'Regan, R. M. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/743193 · Cited by 547

Resistance to Trastuzumab in Breast Cancer

Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0636 · Cited by 523

Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and Geldanamycin

Austin, C. D., Mazière, A. M. G. L. D., Pisacane, P. I., van Dijk, S., Eigenbrot, C. W., Sliwkowski, M. X., Klumperman, J., & Scheller, R. H. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-07-0591 · Cited by 507

Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network

Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Spector, N. L., & Blackwell, K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1507 · Cited by 506

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 516

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

Wang, S. E., Narasanna, A., Pérez-Torres, M., Xiang, B., Wu, F. Y., Yang, S., Carpenter, G. F., Gazdar, A. F., Muthuswamy, S. K., & Arteaga, C. L. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.05.023 · Cited by 479

Herceptin: mechanisms of action and resistance

Nahta, R., & Esteva, F. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.041 · Cited by 456

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 465

The Skp2-SCF E3 Ligase Regulates Akt Ubiquitination, Glycolysis, Herceptin Sensitivity, and Tumorigenesis

Chan, C., Li, C., Yang, W., Gao, Y., Lee, S.-W., Feng, Z., Huang, H.-Y., Tsai, K. K., Flores, L. G., Shao, Y., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.065 · Cited by 440

HER2 therapy: Molecular mechanisms of trastuzumab resistance

Nahta, R., & Esteva, F. J. (2006) · Breast Cancer Research · doi:10.1186/bcr1612 · Cited by 443

Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib

Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3148 · Cited by 415

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B. Y., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Rexer, B. N., & Arteaga, C. L. (2012) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.v17.i1.20 · Cited by 377

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

Baselga, J. M., Cortés, J., Im, S., Clark, E., Ross, G. A., Kiermaier, A. C., & Swain, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5384 · Cited by 364

Spatial regulation of receptor tyrosine kinases in development and cancer

Casaletto, J. B., & McClatchey, A. I. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3277 · Cited by 374

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B. E., Kalra, A. V., Paragas, V. B., Bukhalid, R. A., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 363

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.031 · Cited by 344

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

Schaefer, G., Haber, L., Crocker, L., Shia, S., Shao, L., Dowbenko, D. J., Tótpál, K., Wong, A., Lee, C. V., Stawicki, S. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.003 · Cited by 341

Trastuzumab: triumphs and tribulations

Nahta, R., & Esteva, F. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210379 · Cited by 343

Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib

O’Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J. P., O’Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab

Adams, C. W., Allison, D. E., Flagella, K. M., Presta, L. G., Clarke, J. B., Dybdal, N. O., McKeever, K., & Sliwkowski, M. X. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316

Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems

Bird, B., & Swain, S. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1033 · Cited by 314

Mechanisms for oncogenic activation of the epidermal growth factor receptor

Zandi, R., Larsen, A. B., Andersen, P., Stockhausen, M., & Poulsen, H. S. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.06.023 · Cited by 313

Antitumour immunity regulated by aberrant ERBB family signalling

Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288

Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study

Luen, S. J., Salgado, R., Fox, S. B., Savas, P. S., Eng‐Wong, J., Clark, E., Kiermaier, A. C., Swain, S. M., Baselga, J. M., Michiels, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30631-3 · Cited by 279

Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: TBCRC 006

Rimawi, M. F., Mayer, I. A., Forero, A., Nanda, R., Goetz, M. P., Rodriguez, A. A., Pavlick, A. C., Wang, T., Hilsenbeck, S. G., Gutiérrez, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.8027 · Cited by 274

Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer

Tanner, M., Kapanen, A. I., Junttila, T. T., Raheem, O., Grénman, S., Elo, J. P., Elenius, K., & Isola, J. J. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1585.3.12 · Cited by 275

Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

Gianni, L., Lladó, A., Bianchi, G., Cortés, J., Kellokumpu‐Lehtinen, P., Cameron, D., Miles, D. W., Salvagni, S., Wardley, A. M., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 263

Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells

Erjala, K., Sundvall, M., Junttila, T. T., Zhang, N., Savisalo, M., Mali, P., Kulmala, J. A. J., Pulkkinen, J. O., Grenman, R. A., & Elenius, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2404 · Cited by 257

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Xia, W., Gerard, C. M., Liu, L.-H., Baudson, N., Ory, T., & Spector, N. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208774 · Cited by 259

Oncogenes and Tumor Suppressor Genes in Breast Cancer: Potential Diagnostic and Therapeutic Applications

Osborne, C., Wilson, P., & Tripathy, D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-4-361 · Cited by 283

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Gordon, M. S., Matei, D. E., Aghajanian, C. A., Matulonis, U. A., BREWER, M. A., Fleming, G. F., Hainsworth, J. D., García, A. A., Pegram, M. D., Schilder, R. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4221 · Cited by 252

Targeting HER1/EGFR: A molecular approach to cancer therapy

Arteaga, C. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70010-4 · Cited by 252

Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cortés, J., Fumoleau, P., Bianchi, G., Petrella, T. M., Gelmon, K. A., Pivot, X. B., Verma, S., Albanell, J., Conte, P., Lluch, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4207 · Cited by 252

Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

Huang, X., Gao, L., Wang, S., McManaman, J. L., Thor, A. D., Yang, X.-H., Esteva, F. J., & Liu, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3321 · Cited by 252

The ERBB3 receptor in cancer and cancer gene therapy

Sithanandam, G., & Anderson, L. M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.15 · Cited by 240

Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers

Ghosh, R., Narasanna, A., Wang, S. E., Liu, S., Chakrabarty, A., Balko, J. M., Gonzalez-Angulo, A. M., Mills, G. B., Penuel, E. M., Winslow, J. W., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1872 · Cited by 233

Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models

French, D., Lin, B. C., Wang, M.-T., Adams, C. W., Shek, T., Hötzel, K., Bolon, B., Ferrando, R., Blackmore, C., Schroeder, K., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036713 · Cited by 216

Drug delivery approaches for breast cancer

Singh, S. K., Singh, S., Lillard, J. W., & Singh, R. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140325 · Cited by 226

Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4

Albanell, J., Codony, J., Rovira, A., Mellado, B., & Gascón, P. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_21 · Cited by 224

Ligand-induced ErbB receptor dimerization

Lemmon, M. A. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.024 · Cited by 216

Her2-positive breast cancer: Herceptin and beyond

Dean-Colomb, W. M., & Esteva, F. J. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.013 · Cited by 213

Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer

Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., & Wilson, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307649200 · Cited by 201

Molecular Pathways: HER3 Targeted Therapy

Gala, K. P., & Chandarlapaty, S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1549 · Cited by 200

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D. J., Schaefer, G., Miller, K. D., André, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer

Nami, B., Maadi, H., & Wang, Z. (2018) · Cancers · doi:10.3390/cancers10100342 · Cited by 202

Targeting the function of the HER2 oncogene in human cancer therapeutics

Moasser, M. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210478 · Cited by 191

Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3

Chen, C. B., Chernis, G. A., Hoang, V. Q., & Landgraf, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1332660100 · Cited by 190

HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

English, D. P.-G., Roque, D. M., & Santin, A. D. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0024-9 · Cited by 188

HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy

Campbell, M. R., Amin, D. N., & Moasser, M. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1218 · Cited by 187

Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy

Arpino, G., Gutiérrez, C., Weiss, H. L., Rimawi, M. F., Massarweh, S. A., Bharwani, L. D., Placido, S. D., Osborne, C. K., & Schiff, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk151 · Cited by 189

Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Makhija, S. K., Amler, L. C., Glenn, D., Ueland, F. R., Gold, M. A., Dizon, D. S., Paton, V. E., Lin, C., Januario, T., Ng, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3354 · Cited by 186

Targeting of erbB3 receptor to overcome resistance in cancer treatment

Ma, J., Lyu, H., Huang, J., & Liu, B. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-105 · Cited by 176

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors

Garrett, J. T., & Arteaga, C. L. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.9.15045 · Cited by 188

HER-2-targeted therapy: lessons learned and future directions.

Nahta, R., & Esteva, F. J. (2003) · PubMed · Cited by 178

Microfluidic Immuno-Biochip for Detection of Breast Cancer Biomarkers Using Hierarchical Composite of Porous Graphene and Titanium Dioxide Nanofibers

Ali, M. A., Mondal, K., Jiao, Y., Oren, S., Xu, Z., Sharma, A., & Dong, L. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b05648 · Cited by 177

ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium

Fuller, S. J., Sivarajah, K., & Sugden, P. H. (2008) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2008.02.278 · Cited by 177

HER3 signaling and targeted therapy in cancer

Mishra, R., Patel, H. M., Alanazi, S., Yuan, L., & Garrett, J. T. (2018) · Oncology Reviews · doi:10.4081/oncol.2018.355 · Cited by 175

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

Ben-Kasus, T., Schechter, B., Lavi, S., Yarden, Y., & Sela, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812059106 · Cited by 173

Mechanisms of action of therapeutic antibodies for cancer

Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179

Monoclonal antibodies for the treatment of cancer

Shuptrine, C. W., Surana, R., & Weiner, L. M. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.009 · Cited by 177

The Mysterious Ways of ErbB2/HER2 Trafficking

Bertelsen, V., & Stang, E. (2014) · Membranes · doi:10.3390/membranes4030424 · Cited by 180

Molecular predictors of response to trastuzumab and lapatinib in breast cancer

Esteva, F. J., Yu, D., Hung, M., & Hortobágyi, G. N. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.216 · Cited by 170

Pertuzumab: new hope for patients with HER2-positive breast cancer

Capelán, M., Pugliano, L., de Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C. P., Loi, S., & Piccart, M. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds328 · Cited by 174

Transforming Growth Factor β Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab

Wang, S. E., Xiang, B., Guix, M., Olivares, M. G., Parker, J. S., Chung, C. H., Pandiella, A., & Arteaga, C. L. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00787-08 · Cited by 168

Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Swain, S. M., Ewer, M. S., Cortés, J., Amadori, D., Miles, D. W., Knott, A., Clark, E., Benyunes, M. C., Ross, G. A., & Baselga, J. M. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0448 · Cited by 163

Stop signals

Greenwood, E. (2002) · Nature reviews. Cancer · doi:10.1038/nrc892

Blockade of Epidermal Growth Factor- or Heregulin-Dependent ErbB2 Activation with the Anti-ErbB2 Monoclonal Antibody 2C4 Has Divergent Downstream Signaling and Growth Effects

Jackson, J. G., Clair, P. S., Sliwkowski, M. X., & Brattain, M. G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3106 · Cited by 104

Changes in heregulin β1 (HRGβ1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line

Yoo, J.-Y., & Hamburger, A. W. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00004-5 · Cited by 7

Erb-2/HER2 Oncogene in Breast Cancer: Does Bivalency of Growth Factors Drive Tumorigenicity Through Receptor Heterodimerization

Yarden, Y. (1999) · doi:10.21236/ada382955

Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

Grunt, T. W., Saceda, M., Martin, M. B., Lupu, R., Dittrich, E., Krupitza, G., Harant, H., Huber, H. P., & Dittrich, C. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910630417 · Cited by 70